Marksans Pharma Ltd Q1 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/0dg2tqksaa0i6vpv4mjocov4.pdf

Key Takeaways


US Market: Volume Strength, Price Pain

Mark Saldanha: "Challenges remain in the US. But we are moving against the trend out here and we are trying to differentiate ourselves amongst everyone else."

Margin Walk: Inflation Hits, Relief Delayed

Mark Saldanha: "I have my doubts whether this financial year you will see the direct impact of all this happening. So hopefully the next year will be much better than this year."

UK, Europe & Rest of World: Broad-Based Growth


Product Pipeline & Capability Build

Mark Saldanha: "Nowadays ANDAs are not free, so they do charge a huge amount for filings. So, you got to be very selective in your development and filing with a vision that the product can see light after two years."

Capacity, Integration & Capital Allocation

Mark Saldanha: "So, acquisitions and M&A's are very unpredictable. We don't, unless we are nearing something where we believe there could be a possibility of signing something, it is too early to mention that."

Guidance & Commitments

CommitmentSpecificsTimeline
FY23 EBITDA margin15–16%FY23
Gross margin levelRemain at Q1 levelsNext 2–3 quarters
Revenue milestoneTrending toward ₹2,000 croresNext year
R&D spend increaseMigrate from 2% to 4% of salesOver next two years
API backward integrationFile at least 2 DMFs; couple of products fully integrated on licenses2 DMFs this calendar year; integration by next year
US product launches~4 products this year, 4–5 next yearThis year and next year
UK product launches3–4 this year, 6–7 next yearThis year and next year
UK filingsWish list of ~25 productsNext 24 months
US filingsWish list of 12–14 productsNext 24 months
Capacity expansion₹200 crores CapEx for infrastructure and machineryNext 12–18 months
3-year EBITDA margin target19–20% achievableOver next 3 years
Injectables entryNot in near horizonsAt least next 12 months

Key Metrics

MetricQ1 FY23
Operating revenue₹433.8 cr, +24.3% YoY
US & North America revenue₹173.9 cr, +25.7% YoY
EU & UK formulations revenue₹181 cr, +13.7% YoY
Australia & New Zealand revenue₹52.6 cr, +37.8% YoY
Rest of World revenue₹26.3 cr, +99% YoY
Gross margin50.5%, declined 302 bps YoY from 53.5%
EBITDA₹72.9 cr, -5.8% YoY
PAT₹60.2 cr, vs ₹62.6 cr in Q1 FY22 and ₹29.7 cr in Q4 FY22
R&D spend₹8.9 cr, ~2% of sales; target to increase to 4% over next two years
Cash and cash equivalents₹339 cr as of 30th June 2022
US pricing erosionHigh single digits, similar to previous quarter
Capacity utilization~75% across plants
FY23 EBITDA margin guidance15–16% anticipated
US product launches planned~4 products in FY23, 4–5 in FY24
UK product launches planned3–4 products in FY23, 6–7 in FY24